- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05322733
Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL
Efficacy and Safety of Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (oFCG) in the Treatment of Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Jianyong Li, PhD, MD
- Phone Number: 025-83718836
- Email: lijianyonglm@126.com
Study Locations
-
-
Jiangsu
-
Nanjin, Jiangsu, China, 210029
- Recruiting
- Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
-
Contact:
- Huayuan Zhu, PhD,MD
- Phone Number: 86 25 68306034
- Email: huayuan.zhu@hotmail.com
-
Contact:
- Yeqin Sha, MD
- Email: yeqinsha@njmu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age between 18 to 65 years old for both gender.
- Patients have a confirmed diagnosis of CD20-positive chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) and meet criteria to initiate first-line treatment per International Workshop on CLL Working Group (IWCLL) 2018 guidelines
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- At least one measurable disease detected by enhanced computerized tomography (CT) or magnetic resonance imaging (MRI). At least one lymph node with the longest axis >=1.5cm and one measurable vertical dimension.
- With life expectancy > 6 months.
- Patients must meet the following laboratory examination criteria during 14 days before entry:
Serum bilirubin <1.5 Upper Limit of Normal (ULN), other than gilbert syndrome (defined as unconjugated bilirubin>80%); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 ULN.
Absolute neutrophil count (ANC)≥0.75×109/L and Platelets≥50×109/L (patients without exposure to G-CSF or blood transfusion within 7 days and no exposure to )
Exclusion Criteria:
- Cumulative illness rating scale (CIRS) > 6.
- Creatinine clearance rate (Ccr) <70 ml/min calculated by Cockcroft-Gault formula or by 24-hour urine analysis.
- Patients diagnosed as other malignancy except lymphoma, except patients with curative intent and with no known active disease present for ≥ 5 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician.
- Patients with known central nervous system involvement.
- Patients with progressive multifocal leukoencephalopathy (PML).
- Patients with history of Richter's Syndrome or suspected Richter's Syndrome.
- Uncontrolled autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura, e.g. persistent decreasing hemoglobin or platelet count requiring steroid therapy 4 weeks before initiation of study.
- Prior exposure to systemic therapy for CLL/SLL (except for incomplete treatment regimens fewer than 2 weeks such as antitumor steroid therapy).
- Prior exposure to live vaccines, immunotherapy or other investigational therapeutic agent within 4 weeks prior to enrollment.
- Requiring persistent steroid therapy for other non-antitumor purposes. Systemic steroid drug use within 7 days of first dose of study drug except regional use of steroid drug.
Uncontrolled or other serious cardiovascular disease, including:
- New York Heart Association (NYHA) class II or higher congestive heart failure, unstable angina, myocardial infarction, or clinically significant arrhythmia requiring medical intervention with a left ventricular ejection fraction (LVEF) <50% at screening 6 months prior to initial administration of the study drug;
- Primary cardiomyopathy (such as dilated cardiomyopathy, hypertrophic cardiomyopathy, rhythmogenesis right ventricular cardiomyopathy, restricted cardiomyopathy, unshaped cardiomyopathy);
- Clinically significant prolonged QTc interval, or QTc interval >470 ms in female and >450 ms in male at screening;
- Uncontrolled hypertension: on the basis of lifestyle improvement, blood pressure still fails to reach the standard after application of 2 or more kinds of reasonable, tolerable and full dose antihypertensive drugs (including diuretics), or 4 or more kinds of antihypertensive drugs until blood pressure can be effectively controlled.
- Active bleeding within 2 months prior to screening, or taking anticoagulant/platelet drugs, or have a definite bleeding tendency in the investigator's opinion (e.g., esophageal varices with bleeding risk, local active ulcer lesions);
- History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
- Clinically significant gastrointestinal abnormalities that may affect drug ingestion, transport, or absorption (e.g., inability to swallow, chronic diarrhea, intestinal obstruction, etc.), or total gastrectomy.
- Major surgery within 4 weeks of first dose of study drug. Diagnostic examination is not regarded as surgery and insertion of vascular access device excluded from the criteria.
- Uncontrolled active systemic fungi, bacteria, virus (e.g. CMV DNA positive by PCR analysis) or other infections (defined as showing persistent symptoms of infection and no improvement although appropriate antibiotics or other treatment have been applied), or requiring intravenous (IV) antibiotics administration.
- Known human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection (positive results from PCR analysis).
- Known hypersensitivity to Orelabrutinib, Fludarabine, Cyclophosphamide or Obinutuzumab
- Concurrent treatment with strong or moderate cytochrome P450, family 3, subfamily A (CYP3A) inhibitors or inducers.
- Any mental or cognitive impairment that may limit their understanding of informed consent and compliance with the study.
- Pregnant and lactating women, or women of childbearing age who are unwilling to use contraception throughout the study period and within 18 months of the last administration of obinutuzumab or within 180 days of the last administration of any other study drug (women who were fertile must have a negative serological pregnancy test within 14 days prior to initiation of study) Male without surgically sterilized who are unwilling to use contraception throughout the study period and within 180 days of the last administration of the study drug.
- Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment (oFCG)
See Detailed Description.
|
150 mg capsules administered orally once daily (28-day cycles).
Until 12 or 24 cycles and following BM undetectable MRD, or disease progression, or intolerant toxicity.
Other Names:
1000 mg administered intravenously once on Day 1, 8, 15 of first cycle and on Day 1 of following cycles for maximal 12 cycles (28-day cycles).
Other Names:
25mg/m2/day administered intravenously on Day 1-3 for every cycle (at most 6 cycles, 28-day cycles).
Other Names:
250mg/m2/day administered intravenously on Day 1-3 for every cycle (at most 6 cycles, 28-day cycles).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
BM undetectable MRD rate after 6 cycles
Time Frame: at the end of 6 cycles(each cycle is 28 days)
|
Participants who achieve bone marrow (BM) undetectable Minimal Residue Disease (uMRD) after 6 cycles detecting by four-color flow cytometry with a detection level of 10-4.
|
at the end of 6 cycles(each cycle is 28 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
BM and PB undetectable MRD ratev after 3, 12, 24 cycles.
Time Frame: at the end of 3, 12, 24 cycles(each cycle is 28 days)
|
participants who achieve BM uMRD (<10-4) on other important evaluation time-point (e.g. after 3, 12 and 24 cycles) except after 6 cycles.
participants who achieve peripheral blood (PB) uMRD (<10-4) on important evaluation time-point.
|
at the end of 3, 12, 24 cycles(each cycle is 28 days)
|
Objective Response Rate (ORR)
Time Frame: at the end of 3, 6 cycles and up to approximately 3 years.(each cycle is 28 days)
|
Response assessed after 3 and 6 cycles and up to approximately 3 years.
|
at the end of 3, 6 cycles and up to approximately 3 years.(each cycle is 28 days)
|
Complete Remission Rate (CRR)
Time Frame: at the end of 3, 6 cycles and up to approximately 3 years.(each cycle is 28 days)
|
Response assessed after 3 and 6 cycles and up to approximately 3 years.
|
at the end of 3, 6 cycles and up to approximately 3 years.(each cycle is 28 days)
|
Duration of Response (DOR)
Time Frame: up to approximately 2, 3 years
|
DOR is defined as duration in days from the data of initial documentation of objective response to the date of first documented evidence of progressive disease (PD) or death from any cause.
Response and PD are defined according to iwCLL 2018 guidelines.
|
up to approximately 2, 3 years
|
Progression Free Survival (PFS)
Time Frame: up to 3 years
|
PFS is defined as duration from the date of enrollment to date of progressive disease, replase, or death from any cause, whichever occurs first.
PD are defined according to iwCLL 2018 guidelines.
|
up to 3 years
|
Overall Survival (OS)
Time Frame: up to 3 years
|
OS is defined as the time from the date of enrollment to the date of the participant's death from any cause.
|
up to 3 years
|
Incidence of adverse events (AEs)
Time Frame: through study completion, an average of 4 year"
|
Treatment emergent adverse events (TEAE), severe adverse events (SAEs), adverse events of special interest (AESIs) and therapy-related AEs will be recorded and graded will be summarized by grade according to CTCAE (version 5.0).
|
through study completion, an average of 4 year"
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PB and BM Undetectable MRD rate by Next-generation Sequencing (NGS ) after 3, 6, 12 and 24 cycles.
Time Frame: at the end of 3, 6, 12 and 24 cycles(each cycle is 28 days)
|
Participants who achieve BM and PB uMRD (<10-6) detected by NGS after 3 and 6 cycles.
Participants who achieve BM uMRD (<10-6) detected by NGS after 12 and 24 cycles.
|
at the end of 3, 6, 12 and 24 cycles(each cycle is 28 days)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jianyong Li, PhD, MD, The First Affiliated Hospital with Nanjing Medical University
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Leukemia, B-Cell
- Lymphoma
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Immunological
- Cyclophosphamide
- Fludarabine
- Obinutuzumab
Other Study ID Numbers
- CWCLL-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
Ohio State University Comprehensive Cancer CenterMorphoSys AGActive, not recruitingRecurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Contiguous Stage II Small Lymphocytic... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedChronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage I Small Lymphocytic Lymphoma | Stage III Chronic Lymphocytic Leukemia and other conditionsUnited States
-
National Cancer Institute (NCI)TerminatedChronic Lymphocytic Leukemia | Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedChronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage I Small Lymphocytic Lymphoma | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia and other conditionsUnited States
-
National Cancer Institute (NCI)TerminatedB-cell Chronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Contiguous Stage II Small Lymphocytic Lymphoma | Noncontiguous Stage II Small Lymphocytic Lymphoma | Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Noncontiguous Stage II Small Lymphocytic LymphomaUnited States
-
Virginia Commonwealth UniversityGilead SciencesWithdrawnChronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL | Refractory Small Lymphocytic Lymphoma | SLL | Relapsed CLL | Relapsed Chronic Lymphocytic Leukemia | Relapsed Small Lymphocytic Lymphoma
-
Case Comprehensive Cancer CenterCephalonTerminatedRecurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
BeiGeneRecruitingLymphoma | Leukemia | Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Relapsed Chronic Lymphocytic LeukemiaChina
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingRecurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma | Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaUnited States
Clinical Trials on Orelabrutinib
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingSystemic Lupus Erythematosus, SLEChina
-
Ruijin HospitalRecruitingPrimary Central Nervous System LymphomaChina
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingChronic Primary Immune Thrombocytopenia (ITP)China
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingHepatic ImpairmentChina
-
InnoCare Pharma Inc.Beijing InnoCare Pharma Tech Co., Ltd.Recruiting
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingPrimary Immune ThrombocytopeniaChina
-
Shandong Provincial HospitalRecruitingMantle Cell Lymphoma | Diffuse Large B-cell Lymphoma | High Grade B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | B-cell NonHodgkin LymphomaChina
-
The First Affiliated Hospital with Nanjing Medical...Not yet recruitingLymphoma, Large B-Cell, Diffuse Neoplasms by Histologic TypeChina
-
Wang XinRecruiting
-
Peking University People's HospitalRecruiting